rufinamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3534 106308-44-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rufinamide
  • inovelon
  • banzel
  • CGP-33101
  • CGP 33101
The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel.
  • Molecular weight: 238.20
  • Formula: C10H8F2N4O
  • CLOGP: 0.51
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 73.80
  • ALOGS: -2.57
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.06 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 191.92 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Jan. 16, 2007 EMA Eisai Ltd
Nov. 14, 2008 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 258.32 51.01 92 746 122962 46562262
Status epilepticus 86.05 51.01 24 814 13955 46671269
Stillbirth 73.03 51.01 18 820 6473 46678751
Drug resistance 55.51 51.01 18 820 17350 46667874
Atonic seizures 51.32 51.01 9 829 611 46684613

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 205.33 50.95 81 699 98394 29853304
Status epilepticus 173.69 50.95 43 737 11029 29940669
Aggression 64.46 50.95 27 753 36880 29914818

Pharmacologic Action:

SourceCodeDescription
ATC N03AF03 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Carboxamide derivatives
MeSH PA D000927 Anticonvulsants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Lennox-Gastaut syndrome indication 230418006
Atypical absence seizure off-label use 23374007
Atonic seizure off-label use 42365007
Absence seizure off-label use 79631006
Suicidal thoughts contraindication 6471006
Depressive disorder contraindication 35489007
Hepatic failure contraindication 59927004
Shortened QT interval contraindication 77867006
Leukopenia contraindication 84828003 DOID:615
Disease of liver contraindication 235856003 DOID:409
Renal dialysis contraindication 265764009
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.56 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel alpha subunit Ion channel BLOCKER CHEMBL CHEMBL

External reference:

IDSource
4025270 VUID
N0000179367 NUI
D05775 KEGG_DRUG
4025270 VANDF
C2368829 UMLSCUI
CHEBI:134966 CHEBI
CHEMBL1201754 ChEMBL_ID
129228 PUBCHEM_CID
C079703 MESH_SUPPLEMENTAL_RECORD_UI
7470 IUPHAR_LIGAND_ID
7387 INN_ID
DB06201 DRUGBANK_ID
WFW942PR79 UNII
69036 RXNORM
158992 MMSL
24915 MMSL
340515 MMSL
d07069 MMSL
012301 NDDF
429802008 SNOMEDCT_US
429835003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0425 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0426 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0528 SUSPENSION 40 mg ORAL ANDA 27 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 0378-2330 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 0378-2331 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 31722-598 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 31722-599 TABLET, FILM COATED 400 mg ORAL ANDA 25 sections
Banzel HUMAN PRESCRIPTION DRUG LABEL 1 62856-582 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
Banzel HUMAN PRESCRIPTION DRUG LABEL 1 62856-583 TABLET, FILM COATED 400 mg ORAL NDA 31 sections
Banzel HUMAN PRESCRIPTION DRUG LABEL 1 62856-584 SUSPENSION 40 mg ORAL NDA 31 sections
Rufinamide Human Prescription Drug Label 1 67877-673 SUSPENSION 40 mg ORAL ANDA 23 sections
rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 68462-713 TABLET, FILM COATED 200 mg ORAL ANDA 24 sections
rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 68462-714 TABLET, FILM COATED 400 mg ORAL ANDA 24 sections
Rufinamide HUMAN PRESCRIPTION DRUG LABEL 1 69452-223 SUSPENSION 40 mg ORAL ANDA 28 sections